Scientific Advisory Board

Adam L. Boxer, MD, PhD is the Endowed Professor in Memory and Aging in the Department of Neurology, Weill Institute of Neuroscience, University of California, San Francisco (UCSF). Dr. Boxer directs the Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. 

He is currently, and has been, the Principal Investigator (PI) for a variety of multicenter, randomized, placebo controlled clinical trials in neurodegenerative diseases. He is the PI of the Alzheimer’s Disease Tau Platform (ATP) clinical trial conducted through the NIH Alzheimer’s Clinical Trials Consortium (ACTC). He is co-PI of the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) project focused on preparing for FTD clinical trials, and the FTD Prevention Initiative (FPI), a global collaboration focused on prevention trials in autosomal dominant FTLD. He is PI of the Neurofilament Surveillance Project (NSP) that is developing blood biomarkers for use in FTLD clinical trials. He also leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI) and is contact PI for Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD). 

Günter Höglinger is the Director of the Department of Neurology at the Ludwig-Maximilians-Universität (LMU), and an expert in the design and conduct of clinical trials, in the evaluation of safety and efficacy of molecular interventions with disease-modifying intent. He is also the Senior Scientist at the German Center for Neurodegenerative Diseases (DZNE) and Principal Investigator at the Cluster of Excellence for Systems Neurology (SyNergy), Munich, Germany. His previous experiences include Deputy Director of the Department of Neurology at the Philipps University of Marburg, and Chair of Translational Neurodegeneration at both the Technical University of Munich and DZNE Munich. He was Director of the Department of Neurology at Hannover Medical School and is a member of the Scientific Advisory Board (SAB) of the CurePSP Foundation and co-chair of the SAB of the German Parkinson Foundation. He is a world leader in developing molecular fluid and imaging biomarkers. 

James Rowe is a Professor of Cognitive Neurology, a practising clinical neurologist and an expert on Alzheimer’s disease, Frontotemporal dementia, Progressive Supranuclear Palsy and related disorders. James studied Medical Sciences and Experimental Psychology at Cambridge University before advancing into clinical training at Oxford University; he then obtained his PhD from University College London. Following specialist training in London and Copenhagen, he returned to Cambridge where he now leads the Dementia theme at the National Institute for Health and Care Research (NIHR) Biomedical Research Centre and directs the Cambridge Centre for Frontotemporal Dementia. He is Associate Director of Dementias Platform UK and Chief Scientific Adviser to Alzheimer’s Research UK. His work brings together brain imaging, genetics, pharmacology and cognitive neuroscience to understand the mechanisms of disease to advance new treatment options. 

Dr Samantha Budd Haeberlein, PhD, is an esteemed figure in neurological drug development with international experience at research and executive level in the discovery and development of therapeutics and biomarkers for neurodegenerative diseases. She was previously Senior Vice President and Head of Neurodegeneration at Biogen, where she led and co-led the development of two FDA approved treatments for Alzheimer’s disease, ADUHELM and LEQEMBI, and previously at AstraZeneca, where she held senior roles across Research, Development and Translational Medicine. Samantha currently serves as the Chief Medical Officer at Enigma Biomedical Group, developing solutions for the treatment of neurodegenerative diseases, is on the Board of Directors at Vigil Neuro and is a Senior Advisor to the ICG Life Sciences Investment team.

Henrik Zetterberg, MD, PhD, is a decorated researcher in the field of neurodegenerative diseases. Henrik is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London (UCL), UK, and a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of Department of Psychiatry and Neurochemistry at the University of Gothenburg, leads the UK DRI Fluid Biomarker Laboratory at UCL, and is a Key Member of the Hong Kong Center for neurodegenerative diseases. He is also a Visiting Professor in the UW Department of Medicine, School of Medicine and Public Health, Madison, Wisconsin.

Henrik has developed and researched new diagnostic tests and new preclinical models for Alzheimer’s disease and has been recognised for his influential discoveries as a recipient of numerous prizes such as the Erik K. Fernström Prize for Junior Scientists and the Inga Sandeborg Prize for Research on Alzheimer’s Disease.

Rik Ossenkoppele, PhD, is a renowned academic in neuroscience, working at the intersection of neuroimaging, biomarkers, and cognition in Alzheimer’s disease. Rik is an Associate Professor in Translational Neuroscience and is a Principal Investigator both at the Alzheimer center Amsterdam of the Amsterdam UMC and at Lund University in Sweden. Rik received the European Grand Prix for Research on the Foundation of Alzheimer’s Disease in 2019, the Young Investigator Research award from Alzheimer Nederland in 2020, and the Queen Silvia Research prize in 2021.

Christopher van Dyck, MD, is a leading clinical researcher focusing on neuroimaging and therapeutic studies of Alzheimer’s disease and brain aging. He is a Professor of Psychiatry, Neurology, and Neuroscience and serves as Director of the Alzheimer’s Disease Research Unit, the Alzheimer’s Disease Research Center, and the Division of Aging and Geriatric Psychiatry at Yale School of Medicine.

Alongside his academic positions, Christopher has extensive experience in leading and participating in more than 100 therapeutic trials in Alzheimer’s disease, which include prodromal/ preclinical and brain aging stages. He serves on the Steering and Executive Committee and Co-Chairs the Protocol Evaluation Committee at the Alzheimer’s Clinical Trials Consortium (ACTC). His extensive research has culminated in the lead authorship of the publication of the first disease-modifying treatment for AD (lecanemab) in 2023.